Liquidia Technologies Inc (LQDA)vsViatris Inc (VTRS)
LQDA
Liquidia Technologies Inc
$42.30
+0.05%
HEALTHCARE · Cap: $3.76B
VTRS
Viatris Inc
$17.17
-1.27%
HEALTHCARE · Cap: $20.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 9098% more annual revenue ($14.56B vs $158.32M). VTRS leads profitability with a -2.0% profit margin vs -43.5%. VTRS earns a higher WallStSmart Score of 48/100 (D+).
LQDA
Hold38
out of 100
Grade: F
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LQDA.
Margin of Safety
+33.6%
Fair Value
$24.30
Current Price
$17.17
$7.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 3055.0% year-over-year
Strong operational efficiency at 21.5%
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Trading at 82.9x book value
ROE of -111.1% — below average capital efficiency
Currently unprofitable
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Revenue Growth, Operating Margin. Revenue growth of 3055.0% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.15 suggests the stock is reasonably priced for its growth.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, Price/Book, Return on Equity.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
LQDA profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.87 — expect wider price swings.
LQDA is growing revenue faster at 3055.0% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (48/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?